Bristol partners with Gilead to develop once-daily HIV drug combo

Bristol-Myers Squibb signed a licensing agreement to develop a once-daily HIV tablet that would combine the firm's protease inhibitor Reyataz and Gilead Sciences' experimental booster cobicistat. Gilead began Phase II and III...[more]

Experimental stem cell therapy offers new hope for HIV patients

A hematopoietic stem cell treatment being used experimentally for cancer therapy cleared all traces of HIV from the blood of a leukemia patient, offering new hope for HIV-positive individuals. This finding, along with related...[more]

Study examines short-term hepatitis treatment with Vertex's Incivek

Vertex Pharmaceuticals is launching a clinical trial to examine the effectiveness of Incivek when given as part of a hepatitis C drug cocktail for 12 weeks, instead of 24 or 48. The study involves patients who tend to have a...[more]

IDSA: Raltegravir Continues to Show Efficacy for HIV Response

BOSTON -- Long-term treatment with raltegravir (Isentress), an HIV-1 integrase inhibitor, appeared to improve outcomes for HIV-infected patients compared with treatment based on efavirenz (Sustiva), researchers said here. full...[more]

IDSA: HCV Drug Shows Promise in HIV

BOSTON -- The recently approved hepatitis C drug boceprevir (Victrelis) is effective in patients co-infected with HIV, according to interim results of a phase II study. full story

Source: medpagetoday[more]

Study finds no sign of XMRV transmission in blood

Researchers who evaluated 17,249 samples from blood donors did not find concrete evidence of XMRV transmission, according to a paper introduced Saturday at the AABB Annual Meeting. The researchers used tests intended to identify...[more]

Researchers study human-animal interface for new diseases

A team of researchers is monitoring the human-animal interface for any signs of new viral threats. The researchers are concerned about the potential for animals to serve as mixing vessels for new viruses that will be both deadly...[more]